News Focus
News Focus
icon url

$Pistol Pete$

05/13/17 10:33 PM

#128937 RE: Welcome2Pinkyland #128906

$EQLB Not an "Energy Drink" Last Shot is Nutritious EQLB

http://www.airgofandb.com/#about


Go $EQLB
icon url

$Pistol Pete$

05/14/17 10:49 PM

#129001 RE: Welcome2Pinkyland #128906

$LBRG $.0797
icon url

$Pistol Pete$

05/15/17 1:43 AM

#129022 RE: Welcome2Pinkyland #128906

$EQLB Not an "Energy Drink" Last Shot is Nutritious EQLB

http://www.airgofandb.com/#about


Go $EQLB
icon url

$Pistol Pete$

05/15/17 10:46 AM

#129051 RE: Welcome2Pinkyland #128906

$JCP buy the dip at $4.33
icon url

$Pistol Pete$

05/15/17 11:15 AM

#129056 RE: Welcome2Pinkyland #128906

$MACK $4 is on the deck
icon url

$Pistol Pete$

05/17/17 11:27 AM

#129247 RE: Welcome2Pinkyland #128906

$MACK here is the breakdown to get dividend

1. U need to have shares today to get pay on May 26 but u can't sell your shares until after May 30 otherwise they will take it back

2. U still can purchase shares tomorrow and until May 30 but the dividend pay date will be around June 4th

Hope this help
icon url

$Pistol Pete$

05/17/17 5:56 PM

#129329 RE: Welcome2Pinkyland #128906

$EBYH Chart

icon url

$Pistol Pete$

05/17/17 5:56 PM

#129330 RE: Welcome2Pinkyland #128906

$SSGOF Chart

icon url

$Pistol Pete$

05/17/17 5:57 PM

#129331 RE: Welcome2Pinkyland #128906

$NOXL Chart

icon url

$Pistol Pete$

05/17/17 5:57 PM

#129332 RE: Welcome2Pinkyland #128906

$LBRG Chart

icon url

$Pistol Pete$

05/17/17 5:57 PM

#129333 RE: Welcome2Pinkyland #128906

$ITKH Chart

icon url

$Pistol Pete$

05/17/17 5:58 PM

#129334 RE: Welcome2Pinkyland #128906

$ECOS Chart

icon url

$Pistol Pete$

05/17/17 5:59 PM

#129335 RE: Welcome2Pinkyland #128906

$MLGT Chart

icon url

$Pistol Pete$

05/17/17 5:59 PM

#129336 RE: Welcome2Pinkyland #128906

$TVOG Chart

icon url

$Pistol Pete$

05/17/17 6:00 PM

#129337 RE: Welcome2Pinkyland #128906

$TRKG Chart

icon url

$Pistol Pete$

05/17/17 6:00 PM

#129339 RE: Welcome2Pinkyland #128906

$FERN Chart

icon url

$Pistol Pete$

05/17/17 7:10 PM

#129353 RE: Welcome2Pinkyland #128906

$PMCB Pharmacyte Biotech Inc (OTCMKTS:PMCB) Making A Comeback PMCB



PharmaCyte Biotech, Inc. (OTCMKTS:PMCB), the clinical stage biotechnology company developing medical treatments for cancer and diabetes using the proprietary “Cell-in-a-Box” technology, has recently drawn traders’ attention again. The company is close to an upcoming clinical trial in locally advanced pancreatic cancer. If the company is able to pass this trial, the stock price will become very violent and make an explosive upward move. Some traders are already buying, have a look at the recent upside movements.

Business

PharmaCyte’s technology, Cell-in-a-Box®, is a cellulose-based live cell encapsulation that is used as a platform for the treatment of different types of cancer as well as diabetes. For the treatment of pancreatic cancer, Cell-in-a-Box is used with a combination of low doses of anticancer drug ifosfamide. The combination of both substances is an active “cancer-killing” form. Additionally, the company is also researching the use of its platform for studying the use of cannabinoids for the treatment of cancer. The company believes that this last treatment may help reduce the debilitating side effects usually associated to the cancer treatment. The following picture, found on the website of PMCB, showcases the state of the company’s R&D efforts.




Investors could see from the picture that the most advanced treatment of the company is for the pancreatic cancer. It is involved in the approval of Phase 3 by the FDA, which is the last step before being able to commercialize the product.

Recent Developments

On May 8, 2017, the company released a Q&A article with biotechnology expert Sarah DeMare. Investors can find the press release here. The most important question was made right in the beginning. It was about the list of items that the company has to file in its Investigational New Drug application (IND). The list is quite long. The most important ones are the following:

“(a) Documentation of preclinical work done on the cells.
(b) Toxicology studies.
(c) Documentation of preclinical work done on the capsules themselves.
(d) A wide array of CMC (Chemistry, Manufacturing and Controls) documentation that verifies that the final biologic product (the encapsulated cells) has been produced under current Good Manufacturing Practices (cGMP)-compliant conditions.” Source
In addition, the research disclosed what are the most important points that the FDA will revise, as well as the timing after the process is accepted.

“The FDA is most concerned with patient safety. So, while there may be opportunity to state that certain pieces of information will be available at a later date, those issues that directly impact patient safety are important to include in your IND. From a manufacturing perspective, for a product that is being injected into the body, sterility is of utmost importance to the FDA.” Source
“Following the guidance that the FDA has provided at the pre-IND meeting gives the company the best chance of success at having the IND accepted after the 30-day period.” Source
The timing is quite important for traders as we want to know how long it will take the company take to be able to commercialize the product.

PharmaCyte’s Cannabis Research Program

On April 18, 2017, the company put out another Q&A session with research expert Mark L. Rabe, MD, the Director of PharmaCyte’s Cannabis Program Development. Investors interested can find here the complete interview. We had a look at it and would note the following comments. First of all, we noted that the company did mention that the CBD was useful against cancer.

“Of significance, UNC reported that cannabidiol (CBD), a cannabinoid molecule derived from the Cannabis plant, had anti-cancer effects against several types of cancer cells that were dose-related.” Source
Secondly, Mark L. Rabe noted the size of the market, and the fact that other big companies are also making progress using Cannabis as medicine:

“The current U.S. medical Cannabis industry has been estimated to be worth about $3.0 billion, and it is expected to more than double as more states legalize the use of Cannabis as medicine. There are dozens of companies in the space. Multi-billion-dollar big pharma companies such as Merck, Sanofi-Aventis, AbbVie and Bristol-Meyers Squibb hold cannabinoid-related patents and are conducting cannabinoid-related research.” Source
The investment community is very interested

We went and checked the buzz on the financial forums. We were very surprised with what we found. In total, as of May 16, 2017, there were 1,417 reactions in the Yahoo Finance stock forum. If we take into account the fact that the company does not have a large market capitalization, it means that every movement of the company is extremely studied by the financial community. Thus, if the Phase 3 is accepted, investors should expect a large stock price move.

Solid balance sheet

We were glad to see that the company shows a solid balance sheet. The amount of assets is quite large. Additionally, the amount of cash on the books is remarkable. The only flaw is the amount of intangible assets, which is also elevated.

Period Ending 4/30/2016 4/30/2015 4/30/2014
Current Assets
Cash And Cash Equivalents 1,920.825 2,699.737 3,616.47
Short Term Investments – – –
Net Receivables – – –
Inventory – – –
Other Current Assets 110.026 1,468.281 570.106
Total Current Assets 2,030.851 4,168.018 4,186.576
Long Term Investments 1,572.193 1,572.193 1,572.193
Property Plant and Equipment – – –
Goodwill – – –
Intangible Assets 3,549.427 3,549.427 3,549.427
Accumulated Amortization – – –
Other Assets 7.854 7.854 7.854
Deferred Long Term Asset Charges – – –
Total Assets 7,160.325 9,297.492 9,316.05
Source

Conversely, the amount of liabilities is ten times smaller than the assets and the company has no long term debt:

Current Liabilities
Accounts Payable 487.639 520.366 373.666
Short/Current Long Term Debt – – –
Other Current Liabilities 150 1,000 1,000
Total Current Liabilities 637.639 1,520.366 373.666
Long Term Debt – – –
Other Liabilities – – –
Deferred Long Term Liability Charges – – –
Minority Interest – – –
Negative Goodwill – – –
Total Liabilities 637.639 1,520.366 373.666
Source

Conclusion

The company has very interesting points to note. First of all, the FDA may soon approve the company’s technology for the treatment of Pancreatic Cancer. This is the most important catalyst. Additionally, although the company shows a large amount of shares outstanding, the balance sheet is quite solid and the amount of cash will be sufficient to finance the company’s future operations. To sum up, stay alert, this company may surprise investors in the very near future.
icon url

$Pistol Pete$

05/18/17 8:20 PM

#129405 RE: Welcome2Pinkyland #128906

$GSAT Daily & Weekly Chart



icon url

$Pistol Pete$

05/19/17 8:18 PM

#129465 RE: Welcome2Pinkyland #128906

10 Rock-Solid Dividend Paying Stocks to Own in 2017

https://www.marketbeat.com/slideshows/rock-solid-dividend-payers/1.aspx
icon url

$Pistol Pete$

05/20/17 9:26 PM

#129582 RE: Welcome2Pinkyland #128906

$WEYL Weyland Tech's (WEYL) Partner MOCAAPP Announces Application Sales in the Philippines and Start of Vietnam Marketing

Apr 27, 2017
OTC Disclosure & News Service

-

Weyland Tech's (WEYL) Partner MOCAAPP Announces Application Sales in the Philippines and Start of Vietnam Marketing

HONG KONG, HONG KONG--(Marketwired - April 27, 2017) - Weyland Tech Inc. (OTCQB: WEYL) ("Weyland" or the "Company"), a provider of mobile business applications, announces initial subscriptions and revenues from its South East Asian partner, MOCAAPP. Marketing and development of additional applications -- powered by CreateApp -- continues in the Philippines through the Company's white label channel partner.

According to the Department of Trade and Industry, the Philippines is home to nearly 90,000 Small and Medium businesses ("SMB's") and ~900,000 MSMBs (Micro-Small-Medium-sized-Business) overall. Weyland believes that a substantial number of these businesses will ultimately choose to expand their reach through mobile commerce (m-commerce), which has been the case in the US, Europe, and North Asia.

Leong Yew Poh, Chairman of Weyland's channel partner -- MOCAAPP said, "We are pleased with the ease of use and flexibility of the CreateApp platform and are encouraged by the initial marketing efforts in our partnership with Weyland announced in October of last year."

Concurrently, MOCAAPP indicated initial marketing and trade show efforts have begun in Vietnam.

Weyland believes the expansion of m-commerce in South East Asia is in the early stages and is working with their channel partners to become the mobile on-ramp for e-commerce in the region.

For further information about Weyland Tech, Inc., contact Rich Kaiser, Investor Relations, YES INTERNATIONAL 757-306-6090 (001-757-306-6090), yes@yesinternational.com, info@weyland-tech.com, and http://www.weyland-tech.com/.

Safe Harbor Statement

This release contains certain "forward-looking statements" relating to the business of the Company. All statements, other than statements of historical fact included herein are "forward-looking statements." The statements regarding the continued growth of the mobile app segment and the ability of the Company to continue its expansion into that segment and the ability of the Company to attract customers and partners and generate revenues. Often these forward-looking statements are identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). Expressly, all forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Image Available: http://www.marketwire.com/library/MwGo/2017/4/27/11G137142/Images/weylandmany-9c7cacd36a8fae2fb5ee1225e31c7354.jpg
Contact:
Rich Kaiser
Investor Relations
001-757-306-6090
yes@yesinternational.com
info@weyland-tech.com
www.weyland-tech.com


Copyright © 2017 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
icon url

$Pistol Pete$

05/20/17 9:27 PM

#129583 RE: Welcome2Pinkyland #128906

$GSAT Globalstar Announces First Quarter 2017 Results

COVINGTON, La., May 04, 2017 (GLOBE NEWSWIRE) -- Globalstar, Inc. (NYSE MKT:GSAT) today announced its financial results for the quarter ended March 31, 2017.

Jay Monroe, Chairman and Chief Executive Officer of Globalstar, commented, “In March 2017, our SPOT business reached a significant milestone, enabling the 5,000th rescue since its launch in 2007. SPOT is currently being used by customers to initiate approximately two rescues per day, proving how essential our technology is to saving lives. Our core operations also produced meaningful financial growth with a 13% increase in total revenue as we continue to improve ARPU across all of our major types of revenue. Duplex ARPU was up 26% during the first quarter, contributing significantly to the reduction in net loss and increase in Adjusted EBITDA. We also continue to focus on product and business development through expanding our one-way and two-way product portfolio. Our efforts involve a strong group of internal engineers as well as strategic partners, such as Carmanah, who is currently designing and manufacturing a new solar powered M2M satellite product. Finally, as discussed a couple of months ago, we have initiated requests for authority to provide terrestrial services over our 16.5 MHz of licensed 2.4 GHz spectrum in several international jurisdictions. While we cannot discuss the specific countries we are pursuing, we have a strategy and we will update you as we reach milestones towards our goal."

FIRST QUARTER FINANCIAL REVIEW

Revenue

Total revenue for the first quarter of 2017 increased by $2.9 million, or 13%, from the first quarter of 2016. This increase was driven primarily by higher service revenue resulting from increased ARPU in all major service lines. A slight increase in revenue from subscriber equipment sales also contributed to the increase in total revenue due a higher volume of SPOT units sold during the quarter.

Service revenue increased $2.8 million, or 15%, in the first quarter of 2017 compared to the first quarter of 2016. This increase was driven by growth in both SPOT and Duplex service revenue, which each increased $1.3 million. Higher ARPU propelled this growth, with fluctuations in average subscribers contributing less to the quarter over quarter variances. The 26% and 10% increases in Duplex and SPOT ARPU, respectively, were due primarily to rate plan increases implemented throughout 2016 and the first quarter of 2017 for certain legacy plans to align rates with our service levels. The increase in Duplex ARPU also is attributed to continued popularity of our valuable annual, usage-based plans. These plans result in higher service revenue recognized when unused minutes expire on the anniversary date of the customer's contract. Also contributing to the increase in service revenue was a $0.4 million increase in revenue generated from services performed under a recently awarded government contract.

Subscriber equipment sales revenue increased $0.1 million, or 3%, due primarily to a higher volume of SPOT units sold during the quarter, which resulted in a $0.3 million increase in SPOT equipment sales revenue. Offsetting this increase was a $0.2 million decrease in equipment sales revenue from product sales to our IGOs, which can fluctuate between periods based on demand in their respective international territories.

Loss from Operations

Loss from operations decreased $0.5 million, or 3%, from $15.7 million in the first quarter of 2016 to $15.2 million in the first quarter of 2017 due primarily to a $2.9 million increase in total revenue (for the reasons discussed above), offset partially by a $2.4 million increase in operating expenses. The increase in operating expenses was due in part to a higher cost of services, which was elevated due to expenses to support new product development and our second-generation ground network. Higher management, general and administrative (MG&A) costs also contributed to the increase in operating expenses due to the timing of certain items, including stock compensation expense, subscriber acquisition costs to support sales promotions, and fluctuations in bad debt recoveries and expense between the periods.

Net Loss

Net loss decreased $6.7 million from $26.9 million in the first quarter of 2016 compared to $20.2 million in the first quarter of 2017. The primary reason for this decrease was a $4.6 million fluctuation in non-cash derivative valuation adjustments from a derivative loss in the first quarter of 2016 to a derivative gain in the first quarter of 2017. These fluctuations were driven primarily by changes in certain valuation inputs, including stock price, stock price volatility and the remaining estimated term of the instruments. Changes in other non-cash items, such as gain on equity issuance and foreign exchange gains/losses, also contributed to the decrease in net loss.

Adjusted EBITDA

Adjusted EBITDA increased 23% during the first quarter of 2017 driven primarily by a $2.9 million, or 13%, increase in total revenue, offset partially by a $1.8 million increase in total operating expenses (excluding EBITDA adjustments). The increase in operating expenses during the first quarter of 2017 resulted primarily from higher cost of services and MG&A expenses, offset partially by a slight decrease in cost of subscriber equipment sales. The $1.4 million increase in cost of services was due primarily to higher research and development costs of $0.7 million driven by new products and technology being developed internally and through external partners. Additionally, support costs related to our second-generation ground network increased $0.4 million as the Company accepted the work performed to upgrade its gateways during the fourth quarter 2016. The $0.5 million increase in MG&A expenses (excluding non-cash compensation) resulted primarily from a bad debt recovery being recorded in the first quarter of 2016 that did not recur in 2017.

CONFERENCE CALL

The Company will conduct an investor conference call on May 4, 2017 at 8:30 a.m. ET to discuss its first quarter 2017 financial results.

Details are as follows:
Conference Call: 8:30 a.m. ET
Investors and the media are encouraged to listen to the call through the Investor Relations section of the Company's website at www.globalstar.com/investors. If you would like to participate in the live question and answer session following the Company's conference call, please dial 1 (888) 771-4371 (US and Canada), 1 (847) 585-4405 (International) and use the participant pass code 44675595.

Audio Replay: A replay of the earnings call will be available for a limited time and can be heard after 11:00 a.m. ET on May 4, 2017. Dial: 1 (888) 843-7419 (US and Canada), 1 (630) 652-3042 (International) and pass code 4467 5595#.
About Globalstar, Inc.

Globalstar is a leading provider of mobile satellite voice and data services. Customers around the world in industries such as government, emergency management, marine, logging, oil & gas and outdoor recreation rely on Globalstar to conduct business smarter and faster, maintain peace of mind and access emergency personnel. Globalstar data solutions are ideal for various asset and personal tracking, data monitoring, SCADA and IoT applications. The Company's products include mobile and fixed satellite telephones, the innovative Sat-Fi satellite hotspot, Simplex and Duplex satellite data modems, tracking devices and flexible service packages.

Note that all SPOT products described in this press release are the products of SPOT LLC, a subsidiary of Globalstar, which is not affiliated in any manner with Spot Image of Toulouse, France or Spot Image Corporation of Chantilly, Virginia.

For more information, visit www.globalstar.com.

Investor contact information: kyle.pickens@globalstar.com

Safe Harbor Language for Globalstar Releases
This press release contains certain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Forward-looking statements, such as the statements regarding our expectations with respect to actions by the FCC, future increases in our revenue and profitability and other statements contained in this release regarding matters that are not historical facts, involve predictions. Any forward-looking statements made in this press release are believed to be accurate as of the date made and are not guarantees of future performance. Actual results or developments may differ materially from the expectations expressed or implied in the forward-looking statements, and we undertake no obligation to update any such statements. Additional information on factors that could influence our financial results is included in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.



GLOBALSTAR, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)
(Unaudited)

Three Months Ended March 31,
2017 2016
Revenue:
Service revenues $ 21,481 $ 18,749
Subscriber equipment sales 3,171 3,087
Total revenue 24,652 21,836
Operating expenses:
Cost of services (exclusive of depreciation, amortization, and accretion shown separately below) 8,974 7,591
Cost of subscriber equipment sales 2,096 2,178
Marketing, general and administrative 9,490 8,610
Depreciation, amortization, and accretion 19,294 19,155
Total operating expenses 39,854 37,534
Loss from operations (15,202 ) (15,698 )
Other income (expense):
Gain on equity issuance 706 151
Interest income and expense, net of amounts capitalized (8,828 ) (9,105 )
Derivative gain (loss) 3,223 (1,344 )
Other (24 ) (760 )
Total other income (expense) (4,923 ) (11,058 )
Loss before income taxes (20,125 ) (26,756 )
Income tax expense 36 191
Net loss $ (20,161 ) $ (26,947 )

Net loss per common share:
Basic $ (0.02 ) $ (0.03 )
Diluted (0.02 ) (0.03 )
Weighted-average shares outstanding:
Basic 1,113,968 1,041,028
Diluted 1,113,968 1,041,028


GLOBALSTAR, INC.RECONCILIATION OF GAAP NET INCOME (LOSS) TO NON-GAAP ADJUSTED EBITDA(In thousands)
(Unaudited)

Three Months Ended
March 31,
2017 2016
Net loss $ (20,161 ) $ (26,947 )

Interest income and expense, net 8,828 9,105
Derivative (gain) loss (3,223 ) 1,344
Income tax expense 36 191
Depreciation, amortization, and accretion 19,294 19,155
EBITDA 4,774 2,848

Non-cash compensation 1,318 906
Foreign exchange and other 24 760
Gain on equity issuance (706 ) (151 )
Adjusted EBITDA (1) $ 5,410 $ 4,363


(1 ) EBITDA represents earnings before interest, income taxes, depreciation, amortization, accretion and derivative (gains)/losses. Adjusted EBITDA excludes non-cash compensation expense, reduction in the value of assets, foreign exchange (gains)/losses and certain other significant non-recurring charges as applicable. Management uses Adjusted EBITDA in order to manage the Company's business and to compare its results more closely to the results of its peers. EBITDA and Adjusted EBITDA do not represent and should not be considered as alternatives to GAAP measurements, such as net income/(loss). These terms, as defined by us, may not be comparable to similarly titled measures used by other companies. In light of recent SEC guidance on the use of non-GAAP measures, the Company has recast Adjusted EBITDA in the prior period.

The Company uses Adjusted EBITDA as a supplemental measurement of its operating performance. The Company believes it best reflects changes across time in the Company's performance, including the effects of pricing, cost control and other operational decisions. The Company's management uses Adjusted EBITDA for planning purposes, including the preparation of its annual operating budget. The Company believes that Adjusted EBITDA also is useful to investors because it is frequently used by securities analysts, investors and other interested parties in their evaluation of companies in similar industries. As indicated, Adjusted EBITDA does not include interest expense on borrowed money or depreciation expense on our capital assets or the payment of income taxes, which are necessary elements of the Company's operations. Because Adjusted EBITDA does not account for these expenses, its utility as a measure of the Company's operating performance has material limitations. Because of these limitations, the Company's management does not view Adjusted EBITDA in isolation and also uses other measurements, such as revenues and operating profit, to measure operating performance.


GLOBALSTAR, INC.SCHEDULE OF SELECTED OPERATING METRICS(In thousands, except subscriber and ARPU data)
(Unaudited)

Three Months Ended
March 31,
2017 2016
Service Equipment Service Equipment
Revenue
Duplex $ 7,598 $ 899 $ 6,334 $ 848
SPOT 10,397 1,236 9,101 961
Simplex 2,416 907 2,365 933
IGO 211 139 244 303
Other 859 (10 ) 705 42
$ 21,481 $ 3,171 $ 18,749 $ 3,087

Average Subscribers
Duplex 73,444 77,372
SPOT 278,790 267,523
Simplex 295,576 300,975
IGO 37,768 38,999

ARPU (1)
Duplex $ 34.48 $ 27.29
SPOT 12.43 11.34
Simplex 2.72 2.62
IGO 1.86 2.08


(1 ) Average monthly revenue per user (ARPU) measures service revenues per month divided by the average number of subscribers during that month. Average monthly revenue per user as so defined may not be similar to average monthly revenue per unit as defined by other companies in the Company's industry, is not a measurement under GAAP and should be considered in addition to, but not as a substitute for, the information contained in the Company's statement of operations. The Company believes that average monthly revenue per user provides useful information concerning the appeal of its rate plans and service offerings and its performance in attracting and retaining high value customers.



Source: Globalstar, Inc.
© 2017 GlobeNewswire, Inc.
icon url

$Pistol Pete$

05/20/17 9:28 PM

#129584 RE: Welcome2Pinkyland #128906

$YIPI Yippy, Inc. (YIPI) to Support Globalstar's (GSAT) Software Services Initiative to Market the Worldwide Distribution of Yippy's Data Compression Software and Associated Technologies

Apr 07, 2017
OTC Disclosure & News Service

-

Yippy, Inc. (YIPI) to Support Globalstar's (GSAT) Software Services Initiative to Market the Worldwide Distribution of Yippy's Data Compression Software and Associated Technologies

PR Newswire

ATLANTA, April 7, 2017

ATLANTA, April 7, 2017 /PRNewswire/ -- Yippy, Inc. (OTCMKTS: YIPI) ("Yippy" or the "Company") announced today that it will support Globalstar, Inc.'s (NYSE-MKT: GSAT) ("Globalstar") initiative for the immediate marketing of compression software and intranet data services. Yippy's innovative software platform features advanced data compression technology that significantly decreases webpage load times for internet access and intranet document retrieval. This technology will be made available to millions of existing subscribers for Mobile (MSS) and Fixed (FSS) Satellite Services operators.

Yippy recently completed the production level environment for Globalstar's Generation 2 network and exceeded performance requirements. Subsequently, Yippy presented a plan to the executives of Globalstar which proposed top line growth for both organizations as a result of the distribution of Yippy's software offerings to other service providers and their subscribers worldwide.

"Globalstar and Yippy are entering into another chapter of our relationship," stated Jay Monroe, CEO, Globalstar. "The rollout of this effort has been a major initiative for our satellite operations teams and last year we provided the service on a trial basis. After months of rigorous testing, we have concluded that Yippy's platform provides subscribers with a greatly enhanced data service experience. Additionally, we believe that the technology can be used by operators throughout the satellite industry and we look forward to working with other providers to integrate this technology into their respective platforms."

Recently, Globalstar and Yippy amended the original December 2015 Access Agreement and Securities Agreement that, among other things, included the increase of Yippy's revenue per subscriber by 33% for Globalstar subscribers. The subscription will be offered to all Globalstar Duplex subscribers and will be available for other satellite operators. For these other service providers and their subscribers, Globalstar will pay Yippy 50% of all revenue for the use of Yippy's software technologies. Yippy will pay to Globalstar 30% of the gross margin on the sale of Yippy hardware or for Yippy development services in connection with imbedding Yippy services in other MSS and FSS networks.

"We look forward to providing our Duplex subscribers with an enhanced data service while also enabling other satellite carriers to substantially increase the number and usability of data sessions as subscribers access the web. We have proven that the compression platform materially reduces vital overhead allowing for an enhanced quality of service," commented Jake Rembert, Vice President of US Sales, Globalstar.

"Satellite bandwidth is a finite asset, and most satellite providers have an immediate need to reduce bandwidth overhead per subscriber across their networks. Our compression technology does just that, and is production ready for immediate consumption," stated Richard Granville, CEO, Yippy. He continued, "The typical internet website page downstream has now ballooned to more than 3MB and continues to rise, and satellite executives could not have forecast the substantial increase in concurrent user bandwidth utilization. Even with the launch of enhanced satellites with expanded capacity, we believe compression will prove to be a vital asset to help meet subscriber usage demands. This is not only true of commercial operators, but also government and military satellite networks."

About Yippy, Inc.

Based in Atlanta, GA, Yippy, Inc. is a technology company that specializes in the development of search-based applications, data normalization, compression/optimization and aggregation through enterprise application (app) service environments (EASE). Yippy's proprietary product suites are deployed to provide secure, redundant and maintained data services. The Company also provides the most advanced search appliance and is the best alternative for those seeking a replacement for the Google Search Appliance (GSA). The Company also operates several online internet properties and educational reference portals. Investors can find current financial disclosure for the Company at http://www.otcmarkets.com/stock/YIPI/filings.

Forward-Looking Statements

The information contained herein includes forward-looking statements. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Additional information on risks and other factors that may affect the business and financial results of Yippy, Inc. can be found in the filings of Yippy, Inc. on OTC Markets (www.otcmarkets.com).

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/yippy-inc-yipi-to-support-globalstars-gsat-software-services-initiative-to-market-the-worldwide-distribution-of-yippys-data-compression-software-and-associated-technologies-300436149.html

SOURCE Yippy, Inc.


Copyright © 2017 PR Newswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
icon url

$Pistol Pete$

05/20/17 9:29 PM

#129585 RE: Welcome2Pinkyland #128906

$ECOS Ecolocap Makes Management Changes and Prepares for ECOS Bio-ART Launch in Chicago, IL

Chicago, IL (PRWEB) April 28, 2017

While things have been quiet for EcoloCap over the past few years, their team has worked hard to restructure the company and provide a new outlook for the future. As a continued effort to bring innovative technology to the world, EcoloCap Solutions has decided to implement new management with the retirement of Mr. Siegel as CEO. With the new adjustments in management, EcoloCap has introduced itself to the growing realm of eco-technology; an industry which EcoloCap believes can become a world-leader.

The EcoloCap Solutions' board has voted to elect James Kwak as the new President and CEO. This will take effect on June 1, 2017. James is determined to make EcoloCap a household name. He has a rich background in business development, sales, and building the groundwork for companies to achieve success and to reach their potential. Former CEO, Michael Siegel, will stay on as a director and assume the title of Chief Technology Officer where he will concentrate on developing new applications for the ECOS/Bio-ART technology.

James Kwak states: "With Mr. Siegel's retirement the board felt it was necessary to re-structure our organization so Ecolocap could focus on everyone's strengths and weaknesses. In addition to our previous management, we have added strong members to our team that will help us continuously be ahead of the curve and create new opportunities."

In addition to management changes, EcoloCap has structured a new partnership with Lakeshore Recycling Systems. The LRS partnership will allow EcoloCap to deploy the first installation of the ECOS Bio-ART technology at an LRS facility in Chicago. There has been tremendous buzz around this new technology in that it can truly change the way the world looks at waste management. The new technology will ultimately lead to a more green and sustainable Earth by using biological fermentation technology in an patented, in-vessel aerobic digestion.

When asked about EcoloCap's new technology James further states: "This technology not only applies to the waste industry, but has many beneficial applications towards the farming/agricultural sectors, industrial waste streams and human bio-solids remediation. All of these industries face environmental and regulatory issues that we feel we can make a large impact."

Initially, LRS will be processing 15 tons of organic waste per day. The ECOS technology will eliminate landfilling, decrease the problems associated of handling the waste, such as odors, and increasing revenue through costs savings and output sales.

As one of his first tasks, James raised funds through his own private companies to get the pilot project up and running. The project with LRS is just one example of what EcoloCap can accomplish to showcase it's world-changing technology.

In his final statement, James states, "With the difficulties that our company faced in the market with M-Fuel and Nanotechnology, I felt it was best we re-focus and re-energize our efforts into our aerobic digestion technology that we know is going to change the way our world disposes of its organic waste."

About Ecolocap

The Ecolocap compost technology redirects all organic waste into a valuable byproduct. The byproduct includes organic fertilizers, chicken, fish feed, or biomass in the form of a dry powder or pellet that can be efficiently stored, transported, and spread.

This press release may contain statements of a forward-looking nature regarding future events. These statements are only predictions, and actual events may differ materially. Please refer to documents that EcoloCap Solutions Inc. files from time to time with the Securities and Exchange Commission for a discussion of certain factors that could cause actual results to differ materials from those contained in the forward-looking statements.

Visit Ecolocap.com for more information.

Read the full story at http://www.prweb.com/releases/2017/04/prweb14288360.htm

© (c) 2017 PRWEB.COM Newswire
icon url

$Pistol Pete$

05/21/17 12:07 AM

#129609 RE: Welcome2Pinkyland #128906

$PMCB No other treatment for diabetes currently in trials or available can claim reversal of diabetes without the use of an external device (pump) or subcutaneous device. A few months ago I posted DD regarding the possible side effects of a subcutaneous device. Summarily, here they are:


************************************************************************

The The Cell-in-a-Box®/Melligen cell combo performs an identical function, without the use of a medical device:

http://viacyte.com/technology/device-engineering/

Possible side effects from the device insertion/retraction procedure include, and may not be limited to: pain, bruising or swelling, redness, infection, and/or scarring. There’s a chance the device may be harder to remove if it was placed too deep. There's also a chance of malfunction due to improper insertion depth.
************************************************************************
Additional side effects of medical devices inserted just beneath the skin, otherwise known as subcutaneous, also include: possible sensitivity to the device material (which may/may not cause an allergic reaction) and excessive bleeding. Basically, a medical device increases the complexity of any treatment - never a good thing.
************************************************************************
http://www.healthline.com/diabetesmine/progress-report-diabetes-research-involving-that-c-word#1
************************************************************************
More possible side effects from a subcutaneous device could include fixation problems (device movement), resulting in itching/dry skin. People who suffer from eczema could also experience complications with a subcutaneous device.

Another invaluable trait of the The Cell-in-a-Box®/Melligen cell combo, aside from being completely bioinert, is the ability to allow the Melligen cells to secrete insulin without the need for any external devices. These qualities are imperative to achieving an efficacious treatment capable of producing the desired results, while also completely avoiding any immune system response.
************************************************************************
Additional problems & complications associated with subcutaneous devices may include: skin abscess (requiring an incision and drainage of the area, and a culture of the fluid), lipohypertrophy and lipodystrophy (more info here on both conditions:http://www.healthline.com/health/diabetes/lipohypertrophy)

PharmaCyte's Cell-in-a-Box®/Melligen cell combo requires no device whatsoever to produce insulin. Furthermore, the insulin-producing Melligen cells are protected from the immune system, thereby avoiding an immune system response.
************************************************************************
The four main areas to inject insulin are: abdomen, thigh, hip/buttock and the back of arm - this is where lipohypertrophy and lipodystrophy could obtrude a device location. Insulin injected into the abdomen is absorbed (and therefore put to work) the most quickly. Using the same insulin injection site over and over is not a good idea. Type 1 diabetics are more prone to suffer from lipohypertrophy and lipodystrophy as a result of not rotating insulin injection sites, thereby making a subcutaneous device undesirable.

http://www.healthline.com/health/diabetes/lipohypertrophy

PharmaCyte's Cell-in-a-Box®/Melligen cell combo to treat diabetes eliminates the need for daily/weekly/monthly insulin injections. It also requires no subcutaneous device and elicits no immune response.
************************************************************************
They can all run but they cannot hide from the Cell-in-a-Box® live cell encapsulation technology. ViaCyte isn't the only one going to human trials for diabetes:
http://jdrf.org/westernpa/2014/06/05/exciting-smart-insulin-research-news-this-is-why-we-walk/

Imo, the Cell-in-a-Box®/Melligen cell combo is far superior to any other diabetes treatment in existence and at any stage of testing. T1 diabetics desperately want/need a diabetes treatment which requires nothing on their part in terms of monitoring/maintenance/treatment: no more daily shots, no more testing for blood sugar 3-5 times daily, no more waking up in the middle of the night with hypoglycemia (low blood sugar) and no more maintenance/replacement of insulin pumps. The Cell-in-a-Box®/Melligen cell combo requires no external devices, no insulin pumps and no subcutaneous devices to produce insulin.

Go PharmaCyte Biotech!!!
icon url

$Pistol Pete$

05/22/17 1:01 PM

#129768 RE: Welcome2Pinkyland #128906

$MACK Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Informs On Upcoming Milestones MACK




Merrimack Pharmaceuticals Inc (NASDAQ:MACK) posted that it intends to initiate Phase II clinical trial of MM-121 in subjects with heregulin positive, hormone receptor positive and HER2 negative – metastatic breast cancer, in 2017.

It projects to issue top-line report from planned Phase II clinical trial of ‘MM-121’ as a treatment of non-small cell lung cancer in imminent year. Also, it plans to post top-line report from the ongoing Phase II clinical trial of ‘MM-141’ as a treatment of metastatic pancreatic cancer in imminent year.

The details
In association with the close of the ONIVYDE sale and Merrimack’s basic form of doxorubicin hydrochloride liposome prescription to Ipsen last month, the commercial activities have been recorded in the statement as discontinued businesses. R&D costs stood at $21.6 million for the quarter concluded March 2017, against $28 million for the equivalent period closed March 2016, registering a drop of 23%. This decrease was mainly due to the switch to the improved clinical and preclinical pipeline.

Merrimack posted that G&A expenses stood at $5.6 million for the three-months closed March 2017, versus $6.5 million for the equivalent period closed March 2016, marking a decline of 14%. This decrease was due to lower headcount resulting from the restructuring activities noted in the fourth quarter of preceding year.

Net loss for Merrimack in the three-month closed March 2017 was $29.7 million, or $0.23/share, versus $38.5 million, or $0.33/share, for the three-month completed March 2016.

Last month, Merrimack registered upfront cash payment of $575 million from none other than Ipsen. The capital from this deal was utilized to redeem Senior Secured Notes due in 2022, and almost $20 million of costs connected with the redemption.

On Friday, the stock price of Merrimack gained more than 1% to close the week at $3.49. The market cap of firm now stands around $468 million.
icon url

$Pistol Pete$

05/22/17 7:43 PM

#129869 RE: Welcome2Pinkyland #128906

$EBYH 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:43 PM

#129870 RE: Welcome2Pinkyland #128906

$OMVS 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:44 PM

#129873 RE: Welcome2Pinkyland #128906

$SSGOF 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:45 PM

#129875 RE: Welcome2Pinkyland #128906

$NOXL 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:46 PM

#129878 RE: Welcome2Pinkyland #128906

$EQLB 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:49 PM

#129881 RE: Welcome2Pinkyland #128906

$LBRG 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:50 PM

#129882 RE: Welcome2Pinkyland #128906

$WEYL 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:51 PM

#129885 RE: Welcome2Pinkyland #128906

$SIPC 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:51 PM

#129886 RE: Welcome2Pinkyland #128906

$ITKH 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:52 PM

#129887 RE: Welcome2Pinkyland #128906

$YIPI 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:52 PM

#129888 RE: Welcome2Pinkyland #128906

$PMCB 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:52 PM

#129889 RE: Welcome2Pinkyland #128906

$GSAT 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:53 PM

#129890 RE: Welcome2Pinkyland #128906

$ECOS 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:53 PM

#129891 RE: Welcome2Pinkyland #128906

$MLGT 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:54 PM

#129892 RE: Welcome2Pinkyland #128906

$TVOG 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:54 PM

#129893 RE: Welcome2Pinkyland #128906

$TRKG 6 Months Chart

icon url

$Pistol Pete$

05/22/17 7:55 PM

#129894 RE: Welcome2Pinkyland #128906

$FERN 6 Months Chart

icon url

$Pistol Pete$

05/22/17 8:01 PM

#129907 RE: Welcome2Pinkyland #128906

icon url

$Pistol Pete$

05/22/17 8:01 PM

#129908 RE: Welcome2Pinkyland #128906

icon url

$Pistol Pete$

05/22/17 8:02 PM

#129909 RE: Welcome2Pinkyland #128906

icon url

$Pistol Pete$

05/22/17 8:02 PM

#129910 RE: Welcome2Pinkyland #128906

icon url

$Pistol Pete$

05/22/17 8:07 PM

#129914 RE: Welcome2Pinkyland #128906

icon url

$Pistol Pete$

05/23/17 1:45 AM

#129989 RE: Welcome2Pinkyland #128906

$EQLB Not an "Energy Drink" Last Shot is Nutritious EQLB

http://www.airgofandb.com/#about


Go $EQLB
icon url

$Pistol Pete$

05/23/17 1:40 PM

#130150 RE: Welcome2Pinkyland #128906

$ITKH Teknik Holding Corporation Reports 3Q FY17 Revenues of $499.3 Thousand and Net Income of $76.4 Thousand

May 23, 2017
OTC Disclosure & News Service

-

iTeknik Holding Corporation Reports 3Q FY17 Revenues of $499.3 Thousand and Net Income of $76.4 Thousand

WEST PALM BEACH, FL--(Marketwired - May 23, 2017) - iTeknik Holding Corporation (OTC PINK: ITKH) announced results for their third fiscal quarter ended March 31, 2017.

In the first operating quarter since acquiring the assets that are now operating as its Big Rhino Corporation subsidiary, iTeknik announced revenues of $499.3 thousand with net income of $76.4 thousand for the period.

Fred Wicks, iTeknik's Chairman and CEO said, "The results achieved by our Big Rhino Advertising Agency in our first operating quarter have been outstanding. Kyle Eng, President of Big Rhino, and his phenomenal team continue to produce bottom-line results that impress their automotive and non-automotive clients. Their hard work and dedication to quality are the reasons Big Rhino has already built a strong brand. We are adding new clients every month and as a result, have a solid and growing customer base."

Fred Wicks also said, "In addition to our strong financial results and business growth, we are making major strides in our long-term corporate strategy. We are diligently working on our audit that will allow us to eventually become fully reporting. We are also continuing our search for suitable acquisition and merger partners. We have hired an Investor Relations firm to help us get our message out to a wider community of investors using social media and other innovative tools. All of these efforts are dedicated to increasing the value of our stock for all of our shareholders."

iTeknik Holding Corporation (OTC PINK: ITKH) trades on the OTC Pink tier of the OTC Market For quotes and market information on the company, visit http://www.otcmarkets.com/stock/ITKH/company-info.

About iTeknik Holding Corporation:
iTeknik Holding Corporation's strategy (OTC PINK: ITKH) is to acquire fundamentally sound companies that are market accepted, scalable and demonstrate a quantifiable value proposition. Our focus is in companies that have strong market presence, brand awareness and talented and dedicated management teams. We seek companies with the potential to achieve exceptional performance over time in the Marketing, Advertising and Digital Media space and related technologies. iTeknik lends its operational support, management approach and financial resources to these companies to achieve improvements in revenue and earnings growth as well as positioning in the marketplace. iTeknik Holdings currently operates one wholly owned subsidiary, Big Rhino Corporation. For more information visit our website at www.iteknik.com.

About Big Rhino Corporation:
Big Rhino Corporation is a wholly owned subsidiary of iTeknik Holding Corporation and is a full-service advertising and digital media agency. Big Rhino excels in providing on-strategy, fast, precise and creative marketing solutions that get our clients BIG results. We maintain a nimble in-house creative team with a unique talent for delivering the highest quality creative that we believe is faster than anyone else. When combined with our completely integrated digital, interactive and media teams, our clients have access to a strategic and responsive advertising machine. For more information check us out at www.bigrhino.agency

Safe Harbor: This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.

Contact:

Investor Relations
Tom Nelson
Tenassociates33@gmail.com
480-326-8577


Copyright © 2017 Marketwired. All Rights Reserved

icon url

Welcome2Pinkyland

05/23/17 6:32 PM

#130224 RE: Welcome2Pinkyland #128906

18 charts/ 18 reasons to trade:

1) $EBYH - float 520k -primary focus - match medical marijuana users with the appropriate cannabis strains to treat their specific diseases or symptoms


2) $OMVS - Merger/Acquisition play- Robotic Assistance Devices


3) $SSGOF - The #1 Vacation Rental and Homestay site in the Philippines! http://www.stopsleepgo.com/

4) $NOXL - Merger/Acquisition play - new CEO filed with the NVSOS
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=mh%252fA3CxSHIBe2Dmd6ZhQQA%253d%253d&nt7=0


5) $EQLB - in 7-11 now. big distribution deal inked - equity partner Timbaland - national roll out of last shot© Energy drink.


6) $LBRG - 21m float. Chinese merger play


7) $WEYL - http://createappeuropa.com hot mobile app business. Millions in revenue and profit


8) $SIPC - Major Hemp play - and HEMP BEER http://sippindustries.com/


9) $ITKH - http://www.bigrhino.agency/


10) $YIPI - partnered up with GSAT who trades on NYSE -


11) $PMCB - Cell-in-a-Box® technology,


12) $GSAT- may partner with sprint


13) $ECOS recent 8k - $5m deal with big waste recycling company


14) $MLGT recent 8k - 24m float China merger. Company developing SNACHAT LIKE APP


15) $TVOG acquisition play http://bitumentankers.com/


16) $TRKG - reinstated/new directors/merger play


17) $FERN - reinstated/merger play/updates are coming- per CEO e-mail.


18) $CNCT -per 10q- On May 15, 2017, the Company established a Joint Venture Company